Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior
Yang He,Bas Brouwers,Hesong Liu,Hailan Liu,Katherine Lawler,Edson Mendes de Oliveira,Dong-Kee Lee,Yongjie Yang,Aaron R. Cox,Julia M. Keogh,Elana Henning,Rebecca Bounds,Aliki Perdikari,Vikram Ayinampudi,Chunmei Wang,Meng Yu,Longlong Tu,Nan Zhang,Na Yin,Junying Han,Nikolas A. Scarcelli,Zili Yan,Kristine M. Conde,Camille Potts,Jonathan C. Bean,Mengjie Wang,Sean M. Hartig,Lan Liao,Jianming Xu,Inês Barroso,Jacek Mokrosinski,Yong Xu,I. Sadaf Farooqi
DOI: https://doi.org/10.1038/s41591-022-02106-5
IF: 82.9
2022-12-20
Nature Medicine
Abstract:Serotonin reuptake inhibitors and receptor agonists are used to treat obesity, anxiety and depression. Here we studied the role of the serotonin 2C receptor (5-HT 2C R) in weight regulation and behavior. Using exome sequencing of 2,548 people with severe obesity and 1,117 control individuals without obesity, we identified 13 rare variants in the gene encoding 5-HT 2C R ( HTR2C ) in 19 unrelated people (3 males and 16 females). Eleven variants caused a loss of function in HEK293 cells. All people who carried variants had hyperphagia and some degree of maladaptive behavior. Knock-in male mice harboring a human loss-of-function HTR2C variant developed obesity and reduced social exploratory behavior; female mice heterozygous for the same variant showed similar deficits with reduced severity. Using the 5-HT 2C R agonist lorcaserin, we found that depolarization of appetite-suppressing proopiomelanocortin neurons was impaired in knock-in mice. In conclusion, we demonstrate that 5-HT 2C R is involved in the regulation of human appetite, weight and behavior. Our findings suggest that melanocortin receptor agonists might be effective in treating severe obesity in individuals carrying HTR2C variants. We suggest that HTR2C should be included in diagnostic gene panels for severe childhood-onset obesity.
biochemistry & molecular biology,cell biology,medicine, research & experimental